InMed Pharmaceuticals (INM) announced the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market dated March 27, 2026, notifying it that the closing bid price of the Company’s common shares over a period of 30 consecutive trading days was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) during the February 11, 2026 to March 26, 2026 period. In accordance with applicable Nasdaq procedures, the Company has a period of 180 calendar days following the receipt of the written notice mentioned above to cure the deficiency and regain compliance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INM:
- InMed warned by Nasdaq over minimum bid price non-compliance
- InMed Reports Positive Preclinical Data for Alzheimer’s Candidate
- InMed Pharmaceuticals announces preclinical data on effects of INM-901
- InMed Pharmaceuticals files $50M mixed securities shelf
- InMed outlines 2026 development plans for lead programs